<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126005</url>
  </required_header>
  <id_info>
    <org_study_id>CVN-101</org_study_id>
    <nct_id>NCT04126005</nct_id>
  </id_info>
  <brief_title>Natural History Study of Patients With Canavan Disease, CAN Inform</brief_title>
  <official_title>A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspa Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspa Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is study will use medical records that will allow retrospective data extraction of
      critical milestone and motor function data. In addition, prospective assessments will collect
      data relevant to the natural history of Canavan disease in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CANInform, the Canavan disease natural history study, will be the first multinational effort
      to rigorously gather both retrospective and prospective data from this patient population.
      Data collection will include extraction of retrospective data from medical records of living
      patients and deceased patients, and collection of prospective, longitudinal data from living
      patients and their parent(s)/caregiver(s). Motor function assessments will be performed in
      the home by qualified study team members. In addition, families will be invited to attend
      clinic visits or will be followed by the clinical site remotely for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the natural history of Canavan disease</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To enhance the understanding of the natural history of Canavan disease through retrospective data collection from patient medical records and prospective data collection from living patients, including: Phenotypic characteristics and variability, Genotype</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Canavan Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>(age &lt; 18 months)
In-home visits every 2 months
Clinic assessments every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>(age ≥ 18 months - 3 years)
In-home visits every 4 months
Clinic assessments every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>(age &gt; 3 - 5 years)
In-home visits every 6 months
Clinic assessments every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>(age &gt; 5 years)
In-home visits every 12 months
Clinic assessments every 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <description>(deceased)
• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hematology, blood chemistry, urinalysis, genetic mutation confirmation, antibody testing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Living and deceased patients with Canavan disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet age criteria of a specific cohort.*

          2. Confirmed clinical and biochemical diagnosis of Canavan disease before age 18 months.

          3. Available medical records since birth that permit documentation of disease
             characteristics and developmental milestones.

          4. Parent and/or legal guardian is able to read, understand, and sign the informed
             consent.

               -  In the case of a deceased patient whose parent(s) and/or legal guardian(s) have
                  provided informed consent for study participation, the Investigator will review
                  the patient's medical record(s) to determine study eligibility.

        Exclusion Criteria:

        1. Patient does not meet the Inclusion Criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen M Kirby</last_name>
    <phone>978-479-7640</phone>
    <email>kmk@bridgebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Andonian</last_name>
      <phone>617-724-1379</phone>
      <email>HANDONIAN@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Florian Eichler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danika Anganoo-Khan</last_name>
      <phone>929-455-5629</phone>
      <email>Danika.Anganoo-Khan@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Heather Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Fehrs</last_name>
      <phone>0049(0) 40 7410- 56391</phone>
      <email>info.ld@uke.de</email>
    </contact>
    <investigator>
      <last_name>Annette Bley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aspatx.com</url>
    <description>Aspa Therapeutics Company Website</description>
  </link>
  <link>
    <url>http://treatcanavan.com</url>
    <description>CANinform Study Website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canavan Disease</keyword>
  <keyword>leukodystrophy</keyword>
  <keyword>natural history</keyword>
  <keyword>non-interventional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canavan Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available for researchers using a defined process.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

